date,text,form,accepted_time
2020-07-10," 8-k 1 ea124020-8k_panaceaacquis.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 6, 2020 panacea acquisition corp. (exact name of registrant as specified in its charter) delaware 001-39351 85-0862255 (state or other jurisdiction (commission (i.r.s. employer of incorporation) file number) identification no.) 357 tehama st floor 3 san francisco, ca 94103 (address of principal executive offices) (zip code) (415) 966-0807 (registrant’s telephone number, including area code) not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the securities exchange act of 1934: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-third of one redeemable warrant pana.u new york stock exchange class a common stock, par value $0.0001 per share pana new york stock exchange redeemable warrants, each whole warrant exercisable for one share of class a common stock at an exercise price of $11.50 pana ws new york stock exchange indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company þ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01 other events. on july 6, 2020, panacea acquisition corp. (the “company”) consummated its initial public offering (the “ipo”) of 14,375,000 units (the “units”), including the issuance of 1,875,000 units as a result of the underwriters’ exercise of their option to purchase additional units in full. each unit consists of one share of class a common stock of the company, par value $0.0001 per share (“class a common stock”), and one-third of one redeemable warrant of the company. each whole warrant entitles the holder thereof to purchase one share of class a common stock for $11.50 per share, subject to adjustment. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $143,750,000. substantially concurrently with the closing of the ipo, the company completed the private sale of 390,000 units to the company’s sponsor, ecor1 panacea holdings, llc, and 97,500 units to pa co-investment llc (such units, collectively, the “private placement units”), at a purchase price of $10.00 per private placement unit, generating gross proceeds to the company of $4,875,000. a total of $143,750,000, comprised of proceeds from the ipo and the sale of the private placement units was placed in a u.s.-based trust account at j.p. morgan chase bank, n.a., maintained by continental stock transfer & trust company, acting as trustee. an audited balance sheet as of july 6, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the sale of the private placement units has been issued by the company and is included as exhibit 99.1 to this current report on form 8-k. item 9.01	financial statements and exhibits. 	(d)	exhibits. the following exhibits are filed with this form 8-k: exhibit no. description of exhibits 99.1 audited balance sheet, as of july 6, 2020. 1 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. panacea acquisition corp. date: july 10, 2020 by: /s/ oleg nodelman name: oleg nodelman title: chief executive officer 2 ",8-K,2020-07-10 16:30:35
2020-07-06," 8-k 1 ea123822-8k_panaceaacq.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): july 6, 2020 panacea acquisition corp. (exact name of registrant as specified in its charter) delaware 001-39351 85-0862255 (state or other jurisdiction (commission (i.r.s. employer of incorporation) file number) identification no.) 357 tehama st floor 3 san francisco, ca 94103 (address of principal executive offices) (zip code) (415) 966-0807 (registrant’s telephone number, including area code) not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the securities exchange act of 1934: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-third of one redeemable warrant pana.u new york stock exchange class a common stock, par value $0.0001 per share pana new york stock exchange redeemable warrants, each whole warrant exercisable for one share of class a common stock at an exercise price of $11.50 pana ws new york stock exchange indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company þ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01other events. on july 6, 2020, panacea acquisition corp. (the “company”) consummated its initial public offering (the “ipo”) of 14,375,000 units (the “units”), including the issuance of 1,875,000 units as a result of the underwriters’ exercise of their option to purchase additional units in full. each unit consists of one share of class a common stock of the company, par value $0.0001 per share (“class a common stock”), and one-third of one redeemable warrant of the company. each whole warrant entitles the holder thereof to purchase one share of class a common stock for $11.50 per share, subject to adjustment. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $143,750,000. substantially concurrently with the closing of the ipo, the company completed the private sale of 390,000 units to the company’s sponsor, ecor1 panacea holdings, llc (the “sponsor”), and 97,500 units to pa co-investment llc, an affiliate of one of the underwriters (“cowen investments”) (such units, collectively, the “private placement units”), at a purchase price of $10.00 per private placement unit, generating gross proceeds to the company of $4,875,000. the private placement units are identical to the units sold as part of the units in the ipo except that, as long as the sponsor or cowen investments or their permitted transferees beneficially owns the private placement units, the private placement units (including the underlying securities) are subject to certain transfer restrictions and the holders thereof are entitled to certain registration rights, and the underlying warrants: (1) will not be redeemable by the company; (2) may be exercised by the holders on a cashless basis; and (3) with respect to warrants held by cowen investments, will not be exercisable more than five years from the effective date of the registration statement (file no. 333-239138) in accordance with finra rule 5110(f)(2)(g)(i). a total of $143,750,000, comprised of proceeds from the ipo and the sale of the private placement units, was placed in a u.s.-based trust account at j.p. morgan chase bank, n.a., maintained by continental stock transfer & trust company, acting as trustee. except with respect to interest earned on the funds held in the trust account that may be released to the company to pay its taxes, if any, the funds held in the trust account will not be released from the trust account until the earliest of: (1) the completion of the company’s initial business combination; (2) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the company's amended and restated certificate of incorporation (a) to modify the substance or timing of the company's obligation to allow redemptions in connection with its initial business combination or to redeem 100% of its public shares if the company does not complete its initial business combination within 24 months from the closing of the ipo or (b) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of all of the company’s public shares if it is unable to complete its initial business combination within 24 months from the closing of the ipo, subject to applicable law. in connection with the ipo, the company entered into the following agreements, the forms of which were previously filed as exhibits to the company registration statement (file no. 333-239138): ●amended and restated certificate of incorporation of the company. ●an underwriting agreement, dated june 30, 2020, among the company, cowen and company, llc, as representative of the several underwriters, and needham & company, llc, as qualified independent underwriter. ●a business combination marketing agreement, dated june 30, 2020, between the company and cowen and company, llc. ●a warrant agreement, dated june 30, 2020, between the company and continental stock transfer & trust company, as warrant agent. ●a letter agreement, dated june 30, 2020, among the company, the sponsor, cowen investments and the company’s officers and directors. ●an investment management trust agreement, dated june 30, 2020, between the company and continental stock transfer & trust company, as trustee. ●a registration rights agreement, dated june 30, 2020, among the company, the sponsor, cowen investments and certain other security holders. ●an administrative services agreement, dated june 30, 2020, between the company and ecor1 capital, llc. ●a private placement units purchase agreement, dated june 30, 2020, between the company and the sponsor. ●a private placement units purchase agreement, dated june 30, 2020, between the company and cowen investments. ●a forward purchase agreement, dated june 30, 2020, between the company, ecor1 panacea holdings, llc, ecor1 capital fund, l.p., ecor1 capital fund qualified, l.p. and ecor1 venture opportunity fund, l.p. ●an indemnity agreement, dated june 30, 2020, between the company and oleg nodelman. ●an indemnity agreement, dated june 30, 2020, between the company and scott perlen. ●an indemnity agreement, dated june 30, 2020, between the company and sarah marriott. ●an indemnity agreement, dated june 30, 2020, between the company and scott platshon. 1 ●an indemnity agreement, dated june 30, 2020, between the company and caroline stout. ●an indemnity agreement, dated june 30, 2020, between the company and daniel bradbury. ●an indemnity agreement, dated june 30, 2020, between the company and graham cooper. ●an indemnity agreement, dated june 30, 2020, between the company and faheem hasnain. ●an indemnity agreement, dated june 30, 2020, between the company and shalini sharp. on june 30, 2020, the company issued a press release, a copy of which is attached as exhibit 99.1 to this current report on form 8-k, announcing the pricing of the ipo. item 9.01financial statements and exhibits. 	(d)	exhibits. the following exhibits are filed with this form 8-k: exhibit no. description of exhibits 1.1 underwriting agreement, dated june 30, 2020, among the company, cowen and company, llc, as representative of the several underwriters, and needham & company, llc, as qualified independent underwriter. 1.2 business combination marketing agreement, dated june 30, 2020, between the company and cowen and company, llc. 3.1 amended and restated certificate of incorporation of the company. 4.1 warrant agreement, dated june 30, 2020, between the company and continental stock transfer & trust company, as warrant agent. 10.1 letter agreement, dated june 30, 2020, among the company, the sponsor, cowen investments and the company’s officers and directors. 10.2 investment management trust agreement, dated june 30, 2020, between the company and continental stock transfer & trust company, as trustee. 10.3 registration rights agreement, dated june 30, 2020, among the company, the sponsor, cowen investments and certain other security holders party thereto. 10.4 administrative services agreement, dated june 30, 2020, between the company and ecor1 capital, llc. 10.5 private placement units purchase agreement, dated june 30, 2020, between the company and the sponsor. 10.6 private placement units purchase agreement, dated june 30, 2020, between the company and cowen investments. 10.7 forward purchase agreement, dated june 30, 2020, between the company, ecor1 panacea holdings, llc, ecor1 capital fund, l.p., ecor1 capital fund qualified, l.p. and ecor1 venture opportunity fund, l.p. 10.8 indemnity agreement, dated june 30, 2020, between the company and oleg nodelman. 10.9 indemnity agreement, dated june 30, 2020, between the company and scott perlen. 10.10 indemnity agreement, dated june 30, 2020, between the company and sarah marriott. 10.11 indemnity agreement, dated june 30, 2020, between the company and scott platshon. 10.12 indemnity agreement, dated june 30, 2020, between the company and caroline stout. 10.13 indemnity agreement, dated june 30, 2020, between the company and daniel bradbury. 10.14 indemnity agreement, dated june 30, 2020, between the company and graham cooper. 10.15 indemnity agreement, dated june 30, 2020, between the company and faheem hasnain. 10.16 indemnity agreement, dated june 30, 2020, between the company and shalini sharp. 99.1 press release, announcing the pricing of the ipo. 2 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. panacea acquisition corp. date: july 6, 2020 by: /s/ oleg nodelman name: oleg nodelman title: chief executive officer 3 ",8-K,2020-07-06 16:39:16
